| Citation: |
JIN Shangyi, TIAN Xinping. Interpretation on the Chinese Guideline for the Diagnosis and Treatment of Takayasu's Arteritis (2023)[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 560-566. DOI: 10.12290/xhyxzz.2024-0209
|
Takayasu's arteritis (TAK) is a chronic large vessel vasculitis that involves the aorta and its primary branch arteries, which can result in limb ischemia and organ damage. A clinical practice guideline has been newly developed under the leadership of the National Clinical Medical Research Center for Dermatologic and Immunologic Diseases. This guideline provides evidence-based recommendations on 11 key issues in the management of TAK, covering the diagnosis, clinical evaluation, medical treatment, antithrombotic therapy, surgical intervention as well as pregnancy, and aims to guide the diagnosis and treatment of TAK in clinical practice and improve the outcomes of patients in China. This article interprets the key points of this guideline, in order to promote its application.
| [1] |
Watts R A, Hatemi G, Burns J C, et al. Global epidemiology of vasculitis[J]. Nat Rev Rheumatol, 2022, 18(1): 22-34. DOI: 10.1038/s41584-021-00718-8
|
| [2] |
中华医学会风湿病学分会. 大动脉炎诊断及治疗指南[J]. 中华风湿病学杂志, 2011, 15(2): 119-120.
Rheumatology Branch of the Chinese Medical Association. Guidelines for diagnosis and treatment of Takayasu arteritis[J]. Chin J Rheumatol, 2011, 15(2): 119-120.
|
| [3] |
中华医学会风湿病学分会. 大动脉炎诊治指南(草案)[J]. 中华风湿病学杂志, 2004, 8(8): 502-504. DOI: 10.3760/j:issn:1007-7480.2004.08.017
Rheumatology Branch of the Chinese Medical Association. Diagnosis and treatment guidelines for vasculitis (draft)[J]. Chin J Rheumatol, 2004, 8(8): 502-504. DOI: 10.3760/j:issn:1007-7480.2004.08.017
|
| [4] |
国家皮肤与免疫疾病临床医学研究中心(北京协和医院), 中国医师协会风湿免疫专科医师分会血管炎学组, 海峡两岸医药卫生交流协会风湿免疫病学专业委员会血管炎学组, 等. 中国大动脉炎诊疗指南(2023)[J]. 中华内科杂志, 2024, 63(2): 132-152.
National Clinical Research Center for Dermatologic and Immunologic Diseases(Peking Union Medical College Hospital), Vasculitis Study Group of Chinese Association of Rheumatology and Immunology Physicians, Vasculitis Study Group of Special Committee on Rheumatology and Immunology of Cross Straits Medicine Exchange Association, et al. Chinese guideline for the diagnosis and treatment of Takayasu's arteritis(2023)[J]. Chin J Intern Med, 2024, 63(2): 132-152.
|
| [5] |
Arend W P, Michel B A, Bloch D A, et al. The American college of rheumatology 1990 criteria for the classification of takayasu arteritis[J]. Arthritis Rheum, 1990, 33(8): 1129-1134. DOI: 10.1002/art.1780330811
|
| [6] |
Grayson P C, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis[J]. Ann Rheum Dis, 2022, 81(12): 1654-1660. DOI: 10.1136/ard-2022-223482
|
| [7] |
Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis[J]. Ann Rheum Dis, 2020, 79(1): 19-30. DOI: 10.1136/annrheumdis-2019-215672
|
| [8] |
Kerr G S, Hallahan C W, Giordano J, et al. Takayasu arteritis[J]. Ann Intern Med, 1994, 120(11): 919-929. DOI: 10.7326/0003-4819-120-11-199406010-00004
|
| [9] |
Misra R, Danda D, Rajappa S M, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010)[J]. Rheumatology (Oxford), 2013, 52(10): 1795-1801. DOI: 10.1093/rheumatology/ket128
|
| [10] |
Exley A R, Bacon P A, Luqmani R A, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides[J]. Arthritis Rheum, 1997, 40(2): 371-380. DOI: 10.1002/art.1780400222
|
| [11] |
Aydin S Z, Yilmaz N, Akar S, et al. Assessment of disease activity and progression in Takayasu's arteritis with Disease Extent Index-Takayasu[J]. Rheumatology (Oxford), 2010, 49(10): 1889-1893. DOI: 10.1093/rheumatology/keq171
|
| [12] |
Germanò G, Macchioni P, Possemato N, et al. Contrast-enhanced ultrasound of the carotid artery in patients with large vessel vasculitis: correlation with positron emission tomography findings[J]. Arthritis Care Res (Hoboken), 2017, 69(1): 143-149. DOI: 10.1002/acr.22906
|
| [13] |
Li Z Q, Zheng Z H, Ding J, et al. Contrast-enhanced ultrasonography for monitoring arterial inflammation in Takayasu arteritis[J]. J Rheumatol, 2019, 46(6): 616-622. DOI: 10.3899/jrheum.180701
|
| [14] |
Wang Y, Wang Y H, Tian X P, et al. Contrast-enhanced ultrasound for evaluating arteritis activity in Takayasu arteritis patients[J]. Clin Rheumatol, 2020, 39(4): 1229-1235. DOI: 10.1007/s10067-019-04698-9
|
| [15] |
Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice[J]. Ann Rheum Dis, 2018, 77(5): 636-643. DOI: 10.1136/annrheumdis-2017-212649
|
| [16] |
Writing Group, Reviewer group, Members of EANM Cardiovascular, et al. FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC[J]. Eur J Nucl Med Mol Imaging, 2018, 45(7): 1250-1269. DOI: 10.1007/s00259-018-3973-8
|
| [17] |
Comarmond C, Biard L, Lambert M, et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients[J]. Circulation, 2017, 136(12): 1114-1122. DOI: 10.1161/CIRCULATIONAHA.116.027094
|
| [18] |
Schmidt J, Kermani T A, Bacani A K, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients[J]. Mayo Clin Proc, 2013, 88(8): 822-830. DOI: 10.1016/j.mayocp.2013.04.025
|
| [19] |
Shuai Z Q, Zhang C X, Shuai Z W, et al. Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis[J]. Eur Rev Med Pharmacol Sci, 2021, 25(1): 250-262.
|
| [20] |
Youngstein T, Peters J E, Hamdulay S S, et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-α and IL-6 receptor targeted therapies in refractory Takayasu arteritis[J]. Clin Exp Rheumatol, 2014, 32(3 Suppl 82): S11-S18.
|
| [21] |
Kong X F, Sun Y, Dai X J, et al. Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study[J]. Ann Rheum Dis, 2022, 81(1): 117-123. DOI: 10.1136/annrheumdis-2021-220832
|
| [22] |
Misra D P, Rathore U, Patro P, et al. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis[J]. Clin Rheumatol, 2021, 40(11): 4391-4416. DOI: 10.1007/s10067-021-05743-2
|
| [23] |
Perera A H, Youngstein T, Gibbs R G J, et al. Optimizing the outcome of vascular intervention for Takayasu arteritis[J]. Br J Surg, 2014, 101(2): 43-50.
|
| [24] |
Maz M, Chung S A, Abril A, et al. 2021 American College of Rheumatology/vasculitis foundation guideline for the management of giant cell arteritis and Takayasu arteritis[J]. Arthritis Rheumatol, 2021, 73(8): 1349-1365. DOI: 10.1002/art.41774
|
| [25] |
Risse J, Mandry D, Settembre N, et al. Dramatic response to tocilizumab before emergency surgery in severe active Takayasu disease[J]. Circ Cardiovasc Imaging, 2016, 9(7): e004819. DOI: 10.1161/CIRCIMAGING.116.004819
|
| [26] |
Yang L R, Zhang H M, Jiang X J, et al. Clinical manifestations and longterm outcome for patients with Takayasu arteritis in China[J]. J Rheumatol, 2014, 41(12): 2439-2446. DOI: 10.3899/jrheum.140664
|
| [27] |
Abisror N, Mekinian A, Hachulla E, et al. Analysis of risk factors for complications and adverse obstetrical outcomes in women with Takayasu arteritis: a French retrospective study and literature review[J]. Clin Rheumatol, 2020, 39(9): 2707-2713. DOI: 10.1007/s10067-020-05024-4
|
| [28] |
Comarmond C, Mirault T, Biard L, et al. Takayasu arteritis and pregnancy[J]. Arthritis Rheumatol, 2015, 67(12): 3262-3269.
|
| [29] |
He S P, Li Z, Zhang G Z, et al. Pregnancy outcomes in Takayasu arteritis patients[J]. Semin Arthritis Rheum, 2022, 55: 152016.
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: